HeartBeam (NASDAQ:BEAT – Get Free Report) is projected to announce its Q3 2026 results after the market closes on Thursday, November 12th. Analysts expect HeartBeam to announce earnings of ($0.09) per share and revenue of $0.07 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 12, 2026 at 4:30 PM ET.
HeartBeam (NASDAQ:BEAT – Get Free Report) last posted its quarterly earnings results on Thursday, August 13th. The medical research company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). On average, analysts expect HeartBeam to post ($0.37) EPS for the current fiscal year and ($0.24) EPS for the next fiscal year.
HeartBeam Price Performance
Shares of NASDAQ BEAT opened at $0.42 on Thursday. The stock has a fifty day simple moving average of $0.44 and a two-hundred day simple moving average of $0.85. HeartBeam has a 1-year low of $0.35 and a 1-year high of $4.00.
Analyst Ratings Changes
Several equities research analysts have commented on the stock. Weiss Ratings raised shares of HeartBeam from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 30th. HC Wainwright reiterated a “neutral” rating on shares of HeartBeam in a research report on Tuesday, October 6th. Maxim Group assumed coverage on shares of HeartBeam in a research note on Tuesday, July 14th. They issued a “buy” rating and a $2.00 target price for the company. Finally, Wall Street Zen raised shares of HeartBeam to a “sell” rating in a research report on Saturday, October 10th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, HeartBeam presently has a consensus rating of “Moderate Buy” and a consensus target price of $4.00.
Read Our Latest Stock Report on HeartBeam
HeartBeam Company Profile
HeartBeam, Inc is a medical technology company developing portable and digital solutions for cardiac monitoring. Its proprietary technology is designed to capture, analyze and transmit electrocardiogram (ECG) data outside traditional clinical settings, with a focus on helping identify cardiac events such as atrial fibrillation and heart attacks.
The company’s flagship product is the HeartBeam AIMIGo system, which combines a compact, credit-card-sized ECG device with a smartphone application.
Read More
- Five stocks we like better than HeartBeam
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for HeartBeam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HeartBeam and related companies with MarketBeat.com's FREE daily email newsletter.
